A multiscale approach to targeted docetaxel formulations: combination therapy, nanotechnology, electrospinning and 3D printing—a review
Abstract Background Cancer remains one of the leading causes of death worldwide. Docetaxel, first marketed as ‘Taxotere’, has been approved for use as a chemotherapeutic for management of gastric, breast, neck, head, non-small cell lung cancer and prostate cancer. Main body Taxotere, is a docetaxel...
Main Authors: | Karamot O. Oyediran, Margaret O. Ilomuanya, Chukwuemeka P. Azubuike, Layeni Nurudeen |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-06-01
|
Series: | Bulletin of the National Research Centre |
Subjects: | |
Online Access: | https://doi.org/10.1186/s42269-022-00854-5 |
Similar Items
-
Synthesis and in vitro studies of PLGA-DTX nanoconjugate as potential drug delivery vehicle for oral cancer
by: Gupta P, et al.
Published: (2018-03-01) -
Current problems in the first-line treatment of metastatic breast cancer: focus on the role of docetaxel
by: Filippo Montemurro
Published: (2010-09-01) -
Oligo(Lactic Acid)<sub>8</sub>-Docetaxel Prodrug-Loaded PEG-<i>b</i>-PLA Micelles for Prostate Cancer
by: Lauren Repp, et al.
Published: (2021-10-01) -
Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
by: Mina Tajvidi, et al.
Published: (2017-01-01) -
POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)